Test predicts response to cisplatin treatment, 2/14

February 2014—Myriad Genetics presented clinical data from a research study showing that its HRD (homologous recombination deficiency) test predicted platinum response in patients with triple-negative breast cancer (P=0.0003). The HRD score predicted, with a sensitivity of 100 percent, all of the patients who experienced a complete response after presurgical treatment with platinum. In addition, the results showed that the HRD score was generalizable across all breast cancer subtypes.

In a prior study, 70 percent of patients with an HRD score ≥10 responded to the carboplatin-based treatment, compared with only 20 percent of patients with an HRD score

Myriad's HRD test detects when a tumor has lost the ability to repair double-stranded DNA breaks resulting in increased susceptibility to DNA-damaging drugs. The test includes three DNA-based measures of homologous recombination deficiency, including whole genome tumor loss of heterozygosity profiles (HRD-LOH), telomeric allelic imbalance (HRD-TAI), and large-scale state transitions (HRD-LST). All three scores are highly correlated with defects in BRCA1/2 and are associated with sensitivity to platinum agents.

***Myriad Genetics**, 801-584-3065*